Biocryst Pharmaceuticals (BCRX) Accumulated Expenses (2011 - 2026)

Biocryst Pharmaceuticals' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $119.4 million for Q1 2026.

• Quarterly Accumulated Expenses rose 28.89% year-over-year to $119.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.4 million (up 28.89% YoY) and the FY2025 annual result came in at $126.4 million, up 11.58% from the prior year.
• Accumulated Expenses was $119.4 million for Q1 2026 at Biocryst Pharmaceuticals, down from $126.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $126.4 million in Q4 2025 and bottomed at $63.6 million in Q1 2022.
• A 5-year average of $93.0 million and a median of $89.6 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 216.1% — and 2023, when it dropped 5.53%.
• Biocryst Pharmaceuticals' Accumulated Expenses stood at $87.6 million in 2022, then climbed by 17.49% to $102.9 million in 2023, then gained by 10.12% to $113.3 million in 2024, then climbed by 11.58% to $126.4 million in 2025, then decreased by 5.55% to $119.4 million in 2026.
• Business Quant data shows BCRX's Accumulated Expenses at $119.4 million in Q1 2026, $126.4 million in Q4 2025, and $118.8 million in Q3 2025.